Stocktoria
Lipocine Inc. LPCN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-03-21
Lipocine Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -524.7% | -10.3% | 629.0% | -2423.9% | 19.5% |
| Net margin | -487.1% | 0.1% | 573.6% | -2151.7% | -3.9% |
| FCF margin | — | -11.7% | 416.7% | -2420.5% | -27.4% |
| Return on assets | -56.6% | 0.0% | -71.1% | -28.7% | -1.2% |
| Return on equity | -66.5% | 0.0% | -80.3% | -30.2% | -1.4% |
| Debt / equity | — | — | — | — | 0.04× |
| Current ratio | 6.68 | 14.75 | 8.69 | 20.34 | 8.26 |
| Revenue growth | -82.3% | -492.8% | -670.2% | -96.9% | — |
Source: SEC EDGAR filings · CIK 0001535955 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.